<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lederman, Lynne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Sekeres, Mikkael</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">AZA Plus LEN or VOR Do Not Improve Response Rates in MDS or CMML, Though DFS and OS Still an Open Question</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-14</style></pages><abstract><style  face="normal" font="default" size="100%">Patients with myelodysplastic syndrome and chronic myelomonocytic leukemia, particularly those with high risk disease, have an unmet therapeutic need. Azacitidine monotherapy results in a modest response rate and duration of response. The addition of vorinostat or lenalidomide to azacytidine does not improve overall response rates, but may improve disease-free survival, does increase toxicity, discontinuations, and dose-reductions.</style></abstract><number><style face="normal" font="default" size="100%">55</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>